SG11202001160XA - Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof - Google Patents

Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof

Info

Publication number
SG11202001160XA
SG11202001160XA SG11202001160XA SG11202001160XA SG11202001160XA SG 11202001160X A SG11202001160X A SG 11202001160XA SG 11202001160X A SG11202001160X A SG 11202001160XA SG 11202001160X A SG11202001160X A SG 11202001160XA SG 11202001160X A SG11202001160X A SG 11202001160XA
Authority
SG
Singapore
Prior art keywords
bind
antigen
binding molecules
complement component
target antigen
Prior art date
Application number
SG11202001160XA
Inventor
Brinda Prasad
Andrew Murphy
Karolina Meagher
Peter Mason
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202001160XA publication Critical patent/SG11202001160XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202001160XA 2017-09-29 2018-09-27 Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof SG11202001160XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762565569P 2017-09-29 2017-09-29
US201862654576P 2018-04-09 2018-04-09
PCT/US2018/053064 WO2019067682A1 (en) 2017-09-29 2018-09-27 Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof

Publications (1)

Publication Number Publication Date
SG11202001160XA true SG11202001160XA (en) 2020-03-30

Family

ID=63858177

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001160XA SG11202001160XA (en) 2017-09-29 2018-09-27 Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof

Country Status (16)

Country Link
US (2) US10865236B2 (en)
EP (1) EP3688029A1 (en)
JP (1) JP2021500865A (en)
KR (1) KR20200058525A (en)
CN (1) CN111148758B (en)
AU (1) AU2018341587A1 (en)
BR (1) BR112020004977A2 (en)
CA (1) CA3076632A1 (en)
CL (1) CL2020000755A1 (en)
CO (1) CO2020003948A2 (en)
IL (1) IL273227A (en)
MA (1) MA50659A (en)
MX (1) MX2020002976A (en)
PH (1) PH12020500375A1 (en)
SG (1) SG11202001160XA (en)
WO (1) WO2019067682A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005863A (en) * 2018-11-21 2021-07-16 Regeneron Pharma Anti-staphylococcus antibodies and uses thereof.
EA202192810A1 (en) 2019-06-11 2022-03-05 Регенерон Фармасьютикалз, Инк. ANTIBODIES TO PcrV THAT BIND PcrV, COMPOSITIONS CONTAINING ANTIBODIES TO PcrV AND METHODS OF THEIR APPLICATION

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ATE537190T1 (en) 2006-06-02 2011-12-15 Regeneron Pharma HIGH AFFINE ANTIBODIES AGAINST THE HUMAN IL-6 RECEPTOR
EP2164869A2 (en) * 2007-05-31 2010-03-24 Merck Sharp & Dohme Corp. Antigen-binding proteins targeting s. aureus orf0657n
LT3912643T (en) * 2009-02-13 2023-02-10 Immunomedics Inc. Immunoconjugates with an intracellularly-cleavable linkage
CN102471378B (en) 2009-06-26 2014-04-02 瑞泽恩制药公司 Readily isolated bispecific antibodies with native immuneoglobulin format
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
US20140212409A1 (en) * 2012-08-13 2014-07-31 Kyowa Hakko Kirin Co., Ltd. METHOD FOR INCREASING DEPOSITION OF COMPLEMENT C3b ON BACTERIAL SURFACE AND PHAGOCYTOSIS BY PHAGOCYTE AND A THERAPEUTIC METHOD AND A THERAPEUTIC AGENT FOR BACTERIAL INFECTIONS
JOP20200236A1 (en) * 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EP3640338A1 (en) * 2012-11-06 2020-04-22 Medlmmune, LLC Antibodies to s. aureus surface determinants
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
EP4218409A3 (en) * 2013-03-13 2023-08-30 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
JOP20160154B1 (en) * 2015-07-31 2021-08-17 Regeneron Pharma Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
CA2999385A1 (en) * 2015-09-23 2017-03-30 Regeneron Pharmaceuticals, Inc. Optimized anti-cd3 bispecific antibodies and uses thereof

Also Published As

Publication number Publication date
CN111148758A (en) 2020-05-12
CA3076632A1 (en) 2019-04-04
WO2019067682A1 (en) 2019-04-04
JP2021500865A (en) 2021-01-14
IL273227A (en) 2020-04-30
AU2018341587A1 (en) 2020-04-23
MX2020002976A (en) 2020-07-24
CL2020000755A1 (en) 2020-08-14
MA50659A (en) 2020-08-05
KR20200058525A (en) 2020-05-27
US20210147519A1 (en) 2021-05-20
PH12020500375A1 (en) 2020-12-07
EP3688029A1 (en) 2020-08-05
US10865236B2 (en) 2020-12-15
BR112020004977A2 (en) 2020-10-06
US20190100575A1 (en) 2019-04-04
CN111148758B (en) 2022-12-09
CO2020003948A2 (en) 2020-04-24

Similar Documents

Publication Publication Date Title
HK1255971A1 (en) Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
IL275483A (en) Bi-specific antigen binding molecules
IL289946A (en) Bispecific antibodies against cd3 and cd20
HK1258304A1 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
PL3519437T3 (en) Bispecific antibodies against p95her2
IL259082A (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
EP3527590A4 (en) Anti-egfr and anti-cd3 bispecific antibody and applications thereof
EP3363816A4 (en) Anti-ox40 antibody and application thereof
EP3294766C0 (en) Humanized antibody or fragment thereof specific for cd3
IL270941A (en) Bispecific antibodies that bind cd 123 cd3
GB201709970D0 (en) Bispecific antigen-binding molecules
EP3441086A4 (en) Anti-pd-1 monoclonal antibody
IL263936A (en) Humanized monoclonal antibodies that target ve-ptp (hptp-beta)
IL271832A (en) Bispecific anti pd1-anti tim3 antibodies
ZA202004908B (en) Bispecific antibody
IL271416A (en) Bispecific antibody formulation
IL274502A (en) Anti-ox40 antibodies and uses thereof
IL269577B (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
EP3693013A4 (en) Bispecific antibody
IL273227A (en) Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
IL274676A (en) Bispecific antigen binding construct
GB201820446D0 (en) Antigen binding molecules that bind light
GB201620276D0 (en) Anti-AFB1 Fab antibody